QS Research · Michael Burry's Scion Capital analyst template · 2006
BECTON DICKINSON & CO (BDX)
As of 2026-11-20 · 12/15 boxes filled from SEC filings and market data
Report price $212.78 (close 2026-11-20)
Conclusion: WATCH
Conviction low · base case +17% · downside -30% · upside +31%
At $212.78 the market is pricing BDX at 3.29x TTM EV/Sales and 15.3x TTM EV/EBITDA, and on FY2026 continuing-operations revenue of $19.5B the same $74.06B enterprise value is about 3.80x, above the 3.72x peer median; the stock sits 3.4% below its 52-week high with a one-year return of 12.2%, while the low-single-digit FY2027 revenue guide suggests much of the recovery is already in the price. The earnings are real but not cheap: the 61.5x GAAP P/E is distorted by $693.0M of restructuring and $450.0M of impairments, and the adjusted 27.8x and operating 27.5x sit against a 5.2% ROIC below a 5.5% WACC, so the call is WATCH. The base case is $248.31, +16.7%, on EV/Sales at 3.72x, the peer median EV/Sales across six peers; the downside is $148.89, -30.0%, on -10.0% sales at a compressed EV/Sales of 2.8x (today 3.29x); the upside is $278.11, +30.7%, on the base case's multiple on +12% earnings.
Key numbers
- Share price: $212.78
- Market cap: $57.96B
- Latest financial period: TTM to Jun 30, 2026
- Revenue (TTM): $22.48B
- EV / EBITDA (TTM): 15.3x
- P/E (TTM): 61.5x
- Price / book: 2.37x
- Earnings-quality flags (TTM): Impairments -$450.0M (48% of net income); Restructuring charges -$693.0M (74% of net income)
- P/E, adjusted (TTM): 27.8x
- P/E, operating (tax-normalized) (TTM): 27.5x
- Revenue growth (latest fiscal year): +8.2%
- ROIC (TTM): 5.2%
- WACC: 5.5%
- Economic profit spread: -0.3 pts
The 15 boxes
- ✓ 1. Long-form business notes
BDX's reported base is $16.07B of revenue in FY2020, $21.84B in FY2025 and $22.48B on the TTM to 2026-06-30, with operating income of $912.0M, $2.58B and $2.40B on the same three bases; the TTM net income to common of $942.0M sits far below TTM pre-tax income of $1.88B and TTM operating income of $2.40B, and these sources do not itemize what separates them. Operating cash flow is shown only for FY2020 ($3.54B) and FY2021 ($4.65B), while capital returns have been stepped up to $2.50B of buybacks in the TTM period against $641.0M of cash at FY2025 and $708.0M at the TTM date. The business narrative available is reimbursement and regulatory risk: CMS competitive bidding and China volume-based procurement pressure on price, an amended FDA consent decree plus two warning letters, ethylene oxide sterilization rules, and softer government research funding described in the latest filing.
- ✓ 2. Competitive advantage
BD has scale and distribution reach, but the 10-K describes a fragmented, price/innovation-driven market with low-cost entrants and no single material patent. Revenue was $21.84B in FY2025 and $22.48B in the TTM to 2026-06-30, while operating income was $2.58B in FY2025 but $2.40B in that TTM. The durable advantages look like portfolio breadth, distribution and regulatory capability rather than cost or a single protected product; payer control and competition limit pricing power.
- ✓ 3. 10-Q takeaways
Q3 FY2026 (quarter ended June 30, 2026) revenue rose 5.4% to $4.983B, 4.4% on a foreign currency-neutral basis, but gross margin slipped to 46.4% from 47.3% on tariffs, higher labor costs and El Paso Warning Letter remediation costs. Adjusted diluted EPS from continuing operations rose to $3.23 from $3.08, while GAAP EPS was $1.64 after $437M of after-tax specified items (a $(1.59) per-share drag). Nine-month continuing operating cash flow was $2,104M (up 33.3%) and free cash flow $1.7B, funding $2.250B of buybacks and $875M of dividends while total debt fell to $16,808M. FY2026 guidance was updated on August 6, 2026 to adjusted diluted EPS of $12.62-$12.72 (midpoint raised) with revenue growth toward the high end of a low-single-digit-plus range.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.